Drug-induced liver disease

Medical Clinics of North America

Volumn 84, Issue 5, 2000, Pages 1275-1311

  Lewis, James H ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; ANTITHYROID AGENT; ANTIVIRUS AGENT; BROMFENAC; CARDIOVASCULAR AGENT; CENTRAL STIMULANT AGENT; DICLOFENAC; DISULFIRAM; GASTROINTESTINAL AGENT; HERBACEOUS AGENT; HORMONE DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; METHOTREXATE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARACETAMOL; RILUZOLE; SALICYLIC ACID DERIVATIVE; SULINDAC; TACRINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

AUTOIMMUNE HEPATITIS; BILIARY CIRRHOSIS; BLOOD VESSEL INJURY; CHOLESTASIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG ALCOHOL INTERACTION; DRUG INDUCED DISEASE; DRUG OVERDOSE; GENETIC PREDISPOSITION; HUMAN; INCIDENCE; LIVER TOXICITY; LIVER TUMOR; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0033825738     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70287-X     Document Type: Article

References (228)

1. Cholestatic hepatic injury related to warfarin exposure
2. The natural history of histologically proved drug-induced liver disease
3. Vanishing bite duct syndrome temporally associated with ibuprofen use
4. Hepatocellular injury in a patient receiving rosiglitazone: A case report
5. Serum transaminase elevations as indicators of hepatic injury administration of drugs
6. Fulminant liver failure associated with flutamide therapy for hirsutism
7. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist
8. Nefazodone-induced liver failure: Report of three cases
9. Jaundice after therapy with chlordiazepoxide hydrochloride
10. Tolcapone and fulminant hepatitis
11. Metformin-induced acute hepatitis
12. Rosiglitazone
13. Comparative tolerability of the newer fluoroquinolone antibacterials
14. Hepatotoxicity in drug development: Detection, significance and solutions
15. Diclofenac associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration
16. Sulfone syndrome in a patient receiving steroids for pemphigus
17. Cholestatic jaundice caused by D-penicillamine
18. Hepatotoxicity of drugs used in the treatment of gastrointestinal disorders
19. Reye's syndrome in the United States from 1981 through 1997
20. Drug-induced hepatitis: Clinical aspects
21. The lymphocyte transformation test - A debated method of evaluation of drug allergic hepatic injury
22. Hepatotoxicity following desflurane anesthesia
23. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure
24. Sulfasalazine-induced fulminant hepatitis in pediatric Crohn's disease: Report of 2 cases
25. Evaluation of hepatoprotective activity of Cassia fistula leaf extract
26. Liver reactions to oral low-dose tetracyclines
27. Isoniazid-associated hepatitis in 114 patients
28. Hepatocellular adenomas in patients taking Danazol for hereditary angioedema
29. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways
30. Losartan-induced hepatotoxicity
31. Severe hepatitis in three AIDS patients treated with indinavir
32. Mesalamine induced granulomatous hepatitis
33. Amiodarone-induced severe hepatitis mediated by immunological mechanisms
34. Hepatotoxicity related to intracavernous pharmacotherapy with papaverine
35. Repeat exposure to incremental doses of acetaminophen provides protection against acetaminophen-induced lethality in mice: An explanation for high acetaminophen dosage in humans without hepatic injury
36. Fulminant hepatic failure after repeated exposure to isoflurane anesthesia: A case report
37. Valproic acid hepatic fatalities: III. U.S. experience since 1986
38. Oral or intravenous N-acetylcysteine: Which is the treatment of choice for acetaminophen (paracetamol) poisoning?
39. Acute hepatitis due to fluoxetine therapy
40. Tamoxifen-induced transient multifocal hepatic fatty infiltration
41. Effect of rifampicin on liver function in man
42. Acute liver disease associated with erythomycins, sulfonamides, and tetracyclines
43. Icteric toxic hepatitis associated with riluzole
44. Frequency of flutamide-induced hepatotoxicity in patients with prostate carcinoma
45. Labetalol hepatotoxicity
46. Hepatotoxicity associated with sustained-release niacin
47. Consensus meetings on: Causality assessment of drug-induced liver injury
48. Drug-induced prolonged cholestasis in adults: A histological semiquantitative study demonstrating progressive ductopenia
49. Vanishing bile duct syndrome in drug-induced liver disease
50. Haloperidol-induced chronic cholestatic liver disease
51. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or sub-fulminant liver failure during antituberculous treatment including isoniazid
52. Valproate-associated hepatoxicity and its biochemical mechanisms
53. Causes of jaundice in the elderly: A survey of diagnosis and investigation
54. Estrogen-androgen hepatotoxicity?
55. Quinine-induced hepatotoxicity
56. Halothane hepatitis: Detection of a constitutional susceptibility factor
57. Terbinafine hepatotoxicity: Case report and review of the literature
58. Trazedone-induced hepatotoxicity: A case report with comments on drug-induced hepatoxicity
59. Hemolytic jaundice related to ingestion of indinavir
60. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group
61. Hepatic failure in a patient taking rosiglitazone
62. Isoniazid hepatitis among pregnant and postpartum Hispanic patients
63. Rosiglitazone and hepatic failure
64. Fatal fulminant hepatic failure due to cyproterone acetate
65. Drug-induced hepatic injury: An analysis of 1,100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987
66. Ischemic hepatitis: Clinical and laboratory observations of 34 patients
67. Acarbose-induced hepatic injury
68. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid
69. Liver function in postmenopausal women on estrogen/androgen hormone replacement therapy: A meta-analysis of eight clinical trials
70. Acute hepatitis and drug-related lupus induced by minocycline treatment
71. Glyburide-induced hepatitis
72. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome
73. Free radical scavenging action of mediastinal herbs from Ghana, Thonngia sanguinea on experimentally-induced liver injuries
74. Suspected cross-reactivity of enalapril- and captopril-induced hepatotoxicity
75. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors
76. Isoflurane hepatotoxicity in a patient with a previous history of halothane-induced hepatitis
77. Acute cholestatic hepatitis associated with pravastatin
78. Liver injury related to amoxicillin-clavulanic acid interlobular bile-duct lesions and extrahepatic manifestations
79. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin
80. Therapeutic misadventures with acetaminophen: Hepatotoxicity after multiple doses in children
81. Hepatotoxicity of anesthetics and other central nervous system drugs
82. Drug induced hepatitis associated with anticytoplasmic organelle autoantibodies
83. Fulminant hepatic failure: Summary of a workshop
84. Prolonged cholestasis and progessive hepatic fiberosis following imipramine therapy
85. Tetracycline-induced bile duct paucity and prolonged cholestasis
86. Bromfenac (Duract)-associated hepatic failure requiring liver transplantation
87. Ticlopidine-induced cholestatic hepatitis
88. Hepatic injury associated with the phenothiazines: Clinicopathologic and follow-up study of 36 patients
89. Hepatotoxic effects of anabolic androgenic steroids
90. Drug-induced and toxic granulomatous hepatitis
91. Morphologic spectrum of drug-induced hepatic disease
92. Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents
93. Atorvastatin-induced cholestatic jaundice in a young woman with systemic lupus erythematosus
94. Liver injury from cyclosporine A
95. Disulfiram hypersensitivity hepatitis
96. Immunoallergic drug-induced hepatitis: Lessons from halothane
97. Temporal variation in hepatotoxicity and metabolism of acetaminophen in mice
98. Histopathologic changes associated with fialuridine hepatotoxicity
99. Quinidine-induced hepatitis: A common and reversible hypersensitivity reaction
100. Anticonvulsant hypersensitivity syndrome: Incidence, prevention and management
101. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
102. Fatal liver associated with valproate therapy in a patient with Friedreich's disease: Review of valproate hepatotoxicity in adults
103. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits
104. Omeprazole and the development of acute hepatitis
105. Prolonged cholestatis due to trimethoprim-sulfamethoxazole
106. Hepatotoxicity of transplant immunosuppressive agents
107. Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis
108. Significant changes in serum AST across hepatic histological biopsy grades: Prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis
109. Cholestatic jaundice induced by ciprofloxacin
110. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes
111. Hepatotoxicity of herbal remedies and mushrooms
112. Genetic predisposition to drug-induced hepatoxicty
113. Terfenadine and hepatitis
114. Drug-induced hepatotoxicity
115. NSAID-induced hepatotoxicity
116. Histopathologic analysis of suspected amiodarone hepatotoxicity
117. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlation among 104 patients
118. Methotrexate-induced chronic liver injury: Guidelines for detection and prevention
119. Budd-Chiari syndrome associated with oral contraceptive steroids: Review of treatment of 47 cases
120. Drug-induced autoimmune liver disease
121. Drug and chemical-reduced cholestasis
122. Hepatic injury associated with ketoconazole therapy
123. Enflurane hepatotoxicity: A clinicopathologic study of 24 cases
124. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism: A cohort study
125. Acute liver failure after treatment with nefazodone
126. Floxuridine-induced sclerosing cholangitis: An ischemic cholangiopathy
127. An infectious mononucleosis-like syndrome induced by minocycline: A third pattern of adverse drug reaction
128. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993)
129. Minocycline induced liver injury
130. Terbinafine-induced prolonged cholestatis with reduction of interlobular bile ducts
131. Diagnostic value of specific T-cell reactivity to drugs in 95 cases of drug induced liver injury
132. Pemoline hepatotoxicity in children
133. Cox 2 inhibitor and fulminant hepatic failure
134. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
135. Cholestatic jaundice associated with lovastatin (Mevacor) therapy
136. Isoniazid liver injury: Clinical spectrum pathology and probable pathogenesis
137. Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione
138. Propafenone-induced liver injury: Report of a case and review of the literature
139. Chlorpromazine-induced vanish bile duct syndrome leading to biliary cirrhosis
140. Severe hepatotoxicity associated with bromfenac sodium
141. Halothane-associated hepatitis in a 6-year-old boy: Evidence for native liver regeneration following failed treatment with auxiliary liver transplant
142. Severe acetaminophen toxicity in a patient receiving isoniazid
143. Pemoline-associated hepatic injury
144. Immune mechanisms in tienilic acid associated hepatotoxicity
145. Hepatotoxicity associated with isoniazid preventive therapy: 7-year survey from the public health tuberculosis clinic
146. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis
147. Drug-induced vanishing bile duct syndrome: Response to ursodiol
148. Tamoxifen-induced fatty liver in breast cancer
149. Paracetamol-induced acute liver failure: Prevention and management
150. Cirrhosis with steatohepatitis after adjuvant tamoxifen
151. Liver damage from flucloxacillin, cloxacillin and dicloxacillin
152. Long-term hepatic memory for hypersensitivity to nitrofurantoin
153. Felbamate
154. Felbamate in epilepsia therapy: Evaluating the risks
155. Isoniazid-rifampin fulminant hepatitis: A possible consequence of enhancement of isoniazid hepatotoxicity by enzyme induction
156. Hepatotoxicity associated with ritonavir
157. Flutamide-induced acute hepatitis: Investigation on the role of immunoallergic mechanisms
158. Drug-induced liver disease: A penalty for progress
159. Anti-androgen hepatotoxicity in patients with chronic viral hepatitis
160. Liver transplantation for disulfiram-induced hepatic failure
161. Fatal fulminant hepatitis associated with bromfenac use
162. Possible cholestatic injury from ranitidine with review of the literature
163. Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis
164. Amoxicillin-clavulanate potassium-associated cholestasis
165. Prescribing in liver disease
166. Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin
167. Hepatic veno-occlusive disease associated with the consumption of pyrrolizidine-containing dietary supplements
168. Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: A case series
169. Effects of liver disease on pharmacokinetics: An update
170. Methyldopa hepatitis: A report of six cases and review of the literature
171. Effects of acitretin on the liver
172. Epidemiology of hepatocellular adenoma: The role of oral contraceptive use
173. Transaminase elevation on placebo during phase I trials: Prevalence and significance
174. Terfenadine-induced cholestatic hepatitis
175. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effective analysis
176. Clinical statistics on drug-induced liver injuries: Drug-induced liver injuries in Japan in the last 30 years
177. Retinoid hepatitis
178. Rifampicin hepatitis: A clinical histological study
179. Liver injury from herbs and other botanicals
180. Etiology and prognosis for 295 patients with acute liver failure
181. Acetaminophen toxicity in an urban county hospital
182. Anti-epileptic drug hypersensitivity syndrome
183. Estrogen-induced cholestatis: Clues to pathogenesis and treatment
184. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin
185. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine
186. Alcohol mediated increases in acetaminophen hepatotoxicity: Role of CYP2E and CYP3A
187. The prevalence and incidence of medical conditions in healthy pharmaceutical company employees who volunteer to participate in medical research
188. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose: Analysis of the National Multicenter Study
189. Isoniazid associated hepatitis: A review of available information
190. Hypersensitivity reaction to sulphasalazine with severe hepatotoxicity
191. Prevention and treatment of drug-induced liver disease
192. Predisposition to phenytoin hepatotoxicity assessed in vitro
193. Drug-induced chronic liver disease
194. Hepatic injury associated with the use of nitrofurans: A clinicopathological study of 52 reported cases
195. Cholestatic hepatitis due to anti-bacterial combination of amoxicillin and clavulanic acid (Augmentin)
196. Minocycline and lupuslike syndrome in acne patients
197. Hepatoxicity of antiviral agents
198. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
199. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study
200. Fatal cholestatic jaundice in elderly patients taking benoxaprofen
201. Review article: Methotrexate in gastroenterology - Dangerous villain or simply misunderstood?
202. Sulindac-associated hepatic injury: Analysis of 91 cases reported to the Food and Drug Administration
203. Minocycline-related autoimmune hepatitis: Case series and literature review
204. Molecular pathogenesis of cholestasis
205. Antituberculosis drug-induced hepatotoxicity: The role of hepatitis C virus and the human immunodeficiency virus
206. Drug-induced vascular and sinusoidal lesions of the liver
207. Treatment with aged garlic extract protects against bromobenzene toxicity to precession cut rat liver slices
208. Hepatic dysfunction associated with Troglitazone
209. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease
210. A proposed mechanism for chlorpromazine jaundice - Defective hepatic sulphoxidation combined with rapid hydroxylation
211. Chronic active hepatitis associated with etretinate therapy
212. Association of acetaminophen hepatotoxicity with fasting and ethanol use
213. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin
214. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
215. Disulfiram-induced fulminant hepatitis: Guidelines for liver-panel monitoring
216. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes
217. Trimethoprim-sulfamethoxazide-induced vanishing bile duct syndrome
218. Drug-induced vascular lesions of the liver
219. Cholestatic and hepatocellular injury associated with erythromycin esters: Report of 9 cases
220. Effects of aspirin and acetaminophen on the liver
221. Effects of alcohol on other hepatotoxins
222. Even isoflurane
223. Acetaminophen hepatotoxicity
224. Valproate induced hepatic injury: Analysis of 23 fatal cases
225. Ticrynafen associated hepatic injury: Analysis of 340 cases
226. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure